A PHASE 1, FIRST-IN-HUMAN STUDY OF IMMUNOPET IMAGING OF PD-L1 IN TUMORS USING 89ZR-DFO-REGN3504, AN ANTI-PD-L1 TRACER FOR POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH ADVANCED THORACIC MALIGNANCIES
Study of ImmunoPET Imaging in Patients with Advanced Thoracic Malignancies
Sponsor: Regeneron
Enrolling: Male and Female Patients
IRB Number: AAAS0159
U.S. Govt. ID: NCT03746704
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study involves research and is conducted to determine how safe and effective a study drug called 89Zr-DFO-REGN3504 is. 89Zr-DFO-REGN3504 is investigational, which means it has not been approved by any health authority (like the Food and Drug Administration - FDA) for marketing for any condition. 89Zr-DFO-REGN3504 is being studied as an agent for imaging tumors, and will be administered by infusion (through the vein). Cancers include: esophageal cancer, lung cancer, and stomach cancer.
This study is closed
Investigator
Akiva Mintz, MD, PhD
Do You Qualify?
Are you 18 years or older? Yes No
Do you have an advanced thoracic malignancy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162